Rising Road Accidents Fuel Growth In The Acute Spinal Cord Injury Market: Pivotal Factor Influencing Acute Spinal Cord Injury Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Acute Spinal Cord Injury Market Size Growth Forecast: What to Expect by 2025?
The market size for acute spinal cord injuries has seen significant expansion in the past few years. It is projected to escalate from $6.7 billion in 2024 to $7.08 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The historical growth can be linked to an increasing number of acute spinal cord injuries incidents, heightened awareness about them and their treatment alternatives, an amplified demand for individualized care, growing disposable income levels, as well as increased governmental expenditures on ASCI research and development.

How Will the Acute Spinal Cord Injury Market Size Evolve and Grow by 2029?
The market size for acute spinal cord injuries is predicted to experience substantial expansion in the coming years. The projected growth is set to reach $8.77 billion in 2029, with a compound annual growth rate (CAGR) of 5.5%. The predicted growth during the forecast period is primarily due to advancements in therapeutic interventions, telemedicine adoption, pivot towards patient-centric healthcare models, heightened emphasis on preventive healthcare, and injury prevention. The major trends in the forecast period encompass medical breakthroughs, rehabilitation methods, neuroprotection treatments, psychological support, advocacy, and accessibility.

View the full report here:
https://www.thebusinessresearchcompany.com/report/acute-spinal-cord-injury-global-market-report

What Drivers Are Propelling the Growth of Acute Spinal Cord Injury Market Forward?
The escalation in road accident incidences is predicted to spur the growth of the acute spinal cord injury market. Road accidents, which entail the collision of motor vehicles resulting in severe injuries or even death, can lead to spinal injuries. These injuries can damage the central nervous system and impede nerve transmission necessary for functional and sensory abilities. The severity of the accident's impact can inflict trauma on the cervical, lumbar, or thoracic spine, injuring or severing the spinal cord and resulting in paralysis. For instance, as per a report by the Llywodraeth Cymru / Welsh Government in June 2024, there were 4,348 road casualties reported by police forces in Wales in 2023, marking a 2% hike compared to 2022. Thus, the rising incidences of road mishaps fuel the expansion of the acute spinal cord injury market. Likewise, the acute spinal cord injury market experiences growth from the rising prevalence of clinical trials. Clinical trials are instrumental in facilitating advancements in our understanding and treatment of Acute Spinal Cord Injury (SCI). They involve a systematic examination of new therapies, treatments, or interventions to ensure their safety and efficacy for SCI patients. For example, a report by Xtalks, a digital healthcare company from Canada, in May 2023 revealed that clinicalTrials.gov registered 452,604 clinical studies globally as of May 17, 2023. Out of these, 64,838 studies are actively in search of participants. This signifies a remarkable increase from approximately 365,000 registered trials reported at the beginning of 2021. Consequently, the escalating number of clinical trials stimulates the growth of the acute spinal cord injury market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12960&type=smp

Which Emerging Trends Are Transforming the Acute Spinal Cord Injury Market in 2025?
Leading companies in the acute spinal cord injury market are channeling their efforts towards the development of novel drugs. These industry giants are aiming to provide better treatment outcomes for their clients and maintain their competitiveness in the market. This undertaking has led to the emergence of innovative drugs like LYVISPAH. In July 2022, Amneal Pharmaceuticals, a US-based firm, introduced LYVISPAH to the market. This baclofen oral granule, with concentrations of 5, 10 and 20 mg, has been sanctioned by the U.S. Food and Drug Administration (FDA) for use in treating spasticity linked with multiple sclerosis and other disorders involving the spinal cord. LYVISPAH is effective in managing and alleviating flexor spasms, clones, muscular rigidity, and the pain associated with these conditions. The drug's flexibility of tailored dosage, with single-dose granule packages available in 5 mg, 10 mg, and 20 mg doses, and its bioequivalent nature to oral baclofen tablets makes it a beneficial medication for patients suffering from spinal cord injuries and other spinal cord-related disorders.

What Are the Key Segments in the Acute Spinal Cord Injury Market?
The acute spinal cord injury market covered in this report is segmented -

1) By Type: Complete Spinal Cord Injury, Incomplete Spinal Cord Injury
2) By Diagnosis Type: Laboratory Tests, Imaging Tests
3) By Application: Hospitals, Clinics

Subsegments:
1) By Complete Spinal Cord Injury: Tetraplegia, Paraplegia
2) By Incomplete Spinal Cord Injury: Central Cord Syndrome, Anterior Cord Syndrome, Brown-Séquard Syndrome, Conus Medullaris Syndrome, Cauda Equina Syndrome

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12960&type=smp

Who Are the Key Players Shaping the Acute Spinal Cord Injury Market's Competitive Landscape?
Major companies operating in the acute spinal cord injury market are Pfizer Inc., AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Biogen Inc., Vertex Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Stanford Health Care, BioMarin Pharmaceutical Inc., Neuralstem Inc., Kennedy Krieger Institute, Acorda Therapeutics Inc., Craig Hospital, Omeros Corporation, Lineage Cell Therapeutics Inc., Pharmazz Inc., Asterias Biotherapeutics Inc., Histocell S.L., Athersys Inc., ReNetX Bio, Kringle Pharma Inc., BioArctic AB, BioAxone BioSciences Inc., InVivo Therapeutics Holdings Corp, Geron Corporation, Neuronax SA, Tenax Therapeutics, Eusol Biotech Co. Ltd.

What Geographic Markets Are Powering Growth in the Acute Spinal Cord Injury Market?
North America was the largest region in the acute spinal cord injury market in 2024. The regions covered in acute spinal cord injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12960

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.